Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Merck & Co., Inc.
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
December 16, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
December 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
December 15, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
December 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Issues $1 Billion Inaugural Sustainability Bond
December 13, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Prices $8.0 Billion Debt Offering
December 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
December 07, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
December 06, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
December 03, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
December 01, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces First-Quarter 2022 Dividend
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review
November 30, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
November 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
November 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 24, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Completes Acquisition of Acceleron Pharma Inc.
November 22, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
November 19, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1
November 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
November 18, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
November 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, at American Society of Tropical Medicine and Hygiene (ASTMH) 2021 Annual Meeting
November 17, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event
November 11, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval
November 10, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
November 09, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.
November 08, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 Congress Reinforces Merck’s Commitment to Patients With Melanoma Across Stages of Disease
October 31, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
November 04, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
October 29, 2021
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.